Fatma Betül Çakır

Fatma Betül Çakır

Auto-generated profile, based on publicly available information

Fatma Betül Çakır

İstanbul Medeniyet Üniversitesi

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Palliative and Supportive Care
Verified
Journal Article
Closed access
PDF file
MTMüberra Tanrıverdi
Müberra Tanrıverdi
ECErkan Cakir
Erkan Cakir
MAMuhammed Emin Akkoyunlu
Muhammed Emin Akkoyunlu
FCFatma Betül Cakir
Fatma Betül Cakir
Objective: Sleep is one of the important measurements of the quality of life for children especially suffering from a chronic illness such as cancer. Our aim was to determine the changes in sleep quality and to investigate the effect of virtual reality-based exercise (VRBE) approaches on sleep in patients with acute lymphoblastic leukemia (ALL) off treatment.Method: The participants (ALL and healthy siblings) were evaluated for sleep quality with polysomnography and “Children's Sleep Habit Questionnaire” before and after 12 weeks. The study randomized into two groups: an exercise group who received VRBE in two days in a week, 45 min of each session for 12 weeks and an control group who were managed with supportive measures. The VRBE comprised of aerobic exercise in four different games by Nintendo Wii Fit Plus®.Results: This randomized controlled trial was carried out on 38 participants. Before intervention, ALL patients (n = 24) and healthy siblings (n = 14) had similar sleep quality in terms of polysomnography and Children's Sleep Habit Questionnaire findings. After intervention, total time asleep (p = 0.023), respiratory disturbance index of hypopnea (p = 0.005), apnea/hypopnea index (p = 0.008), and number of apnea (p = 0.028) statistically significant improved.Significance of results: Patients with ALL off treatment had similar values of sleep quality with healthy siblings. Novel types of exercises like VRBE have positive effects on sleep disorders in children with ALL and also healthy siblings. Future studies are needed comparing the different types of interventions.

27 December 2019 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
ECErkan Cakir
Erkan Cakir
AAAyse Ayzit Atabek
Ayse Ayzit Atabek
OCOmer Faruk CALIM
Omer Faruk CALIM
SUSelcuk Uzuner
Selcuk Uzuner
LALina Alshadfan
Lina Alshadfan
FCFatma Betul Cakir
Fatma Betul Cakir

5 March 2013 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
RKRejin Kebudi
Rejin Kebudi
FCFatma Betul Cakir
Fatma Betul Cakir
OGOmer Gorgun
Omer Gorgun
FAFulya Yaman Agaoglu
Fulya Yaman Agaoglu
EDEmin Darendeliler
Emin Darendeliler
Topotecan has recently been used in the treatment of pediatric cancer. We evaluated our experience with the modified combination of vincristine, topotecan, and cyclophosphamide (VTC) given in 3 days, in children with recurrent Ewing sarcoma. Children received vincristine (1.5 mg/m(2)/1st day), cyclophosphamide (600 mg/m(2)/day × 2 days) + mesna, and topotecan (1 mg/m(2)/day × 3 days) every 21 days. A total of 118 courses of VTC were given to 13 patients. One patient received VTC both at first and at second relapse. Thus, 14 relapse episodes in 13 patients were evaluated. After three courses of VTC chemotherapy (CT), two achieved complete response (CR), five achieved partial response, thus an objective response was attained in 7/14 (50%) episodes. Two patients had stable disease and two patients progressed. In three episodes, CR was achieved by surgery before CT. One of them had a second relapse and attained CR with VTC. Median time from diagnosis to relapse was 23 months (5-45 months). Site of relapse was local in four patients, and metastatic in 10 episodes of nine patients. Seven patients are alive, three with no evidence of disease and four alive with disease; six have died of disease. Local treatment was used in 11 episodes. The toxicity of the VTC combination was limited mainly to the hematopoietic system. In conclusion, the modified VTC protocol in 3 days every 3 weeks seems to be effective and tolerable in children and adolescents with recurrent/progressive Ewing sarcoma.

11 November 2018 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
RKRejin Kebudi
Rejin Kebudi
FCFatma Betul Cakir
Fatma Betul Cakir
SBSema Buyukkapu Bay
Sema Buyukkapu Bay
OGOmer Gorgun
Omer Gorgun
PAPelin Altınok
Pelin Altınok
EDEmin Darendeliler
Emin Darendeliler

17 December 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
SÖSonay İnCesoy Özdemi̇r
Sonay İnCesoy Özdemi̇r
NTNurdan Taçyildiz
Nurdan Taçyildiz
AVAli Varan
Ali Varan
RKRejin Kebudi
Rejin Kebudi
BZBülent Zülfi̇kAr
Bülent Zülfi̇kAr
MKMehmet Kantar
Mehmet Kantar
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.

25 July 2011 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
FCF. Betul Cakir
F. Betul Cakir
CTCetin Timur
Cetin Timur
AYAsim Yoruk
Asim Yoruk
ECErkan Cakir
Erkan Cakir
AAAylin Canbolat Ayhan
Aylin Canbolat Ayhan
Although varicella is a benign self-limiting disease in healthy children, it can be fatal when it occurs in immunocompromised hosts. Despite that immunosuppressed children are suggested to require 2 doses of vaccine to achieve seroconversion, conflicting results are reported in the literature. The aim of this study was to investigate the seroconversion status and mean antibody titers at first year after single dose and double doses of varicella vaccination in acute lymphoblastic leukemia patients. Patients with leukemia in remission for at least 1 year who were seronegative for varicella-zoster virus immunoglobulin G (IgG) were vaccinated. Titers above the cutoff level (0.65) were accepted as seroconversion. Seventeen patients were vaccinated with single dose whereas 24 patients were vaccinated with double doses. Mean prevaccination antibody titers were 0.56 ± 0.05 in patients with single dose and 0.51 ± 0.08 in patients with double doses (P > .05, Student t test). The mean antibody titers at first year were 0.61 ± 0.05 in patients with single-dose vaccination (P > .05, Wilcoxon signed-rank test) and 1.48 ± 0.04 in patients with double doses (P < .001, Wilcoxon signed-rank test). Seroconversion after single-dose vaccination was achieved in 29% of patients (n = 5/17) and in 75% of patients with double doses (n = 18/24) at first year (P = .004, chi-square test). These results suggest that seroconversion after single-dose vaccination might not persist at first year in malignancy patients. Double doses should be applied in order to provide long-term seroconversion.